Header

Welcome To Kittery Eye

Welcome to the online home of Kittery Eye – a collaborative effort of Kittery Optometric Associates and Kittery Ophthalmic Consultants. Together, “KOA” and “KOC” have provided comprehensive eye-care to Southern Maine and Seacoast New Hampshire for over 25 years . . . and now we're thrilled to bring the office's resources to our patients via the internet.


– enjoy our site and let us know what you think!”

 
Office Location
Eye Care News
[1/1] MedicineNet Eyesight General
MedicineNet Eyesight General

[1/10] Health Tip: When Something's Stuck in Your Eye

[2/10] Retinal Detachment

[3/10] Study Links Gene to Serious Eye Disease

[4/10] How Sun Time as a Kid Led to Eye Surgery

[5/10] Green Laser Pointers May Be Harmful to Eyes

[6/10] Sjogren's Syndrome

[7/10] Health Tip: Drive Safely in the Dark

[8/10] Health Tip: Why Are My Eyes Red?

[9/10] Lady Gaga-Inspired Lens Fad Draws Warning From Eye Docs

[10/10] Eye Condition May Alter Corneal Transplant Results
[1/1] Eye Health / Blindness News From Medical News Today
Latest Health News and Medical News posted throughout the day, every day.

[1/10] Drug Discovery Tools To Fight Cancer, Blindness To Be Discussed At UB Symposium

[2/10] 'Back-To-School' How To Prevent Sports Related Eye Injuries

[3/10] Carl Zeiss Meditec Is Shaping The Future Of Ophthalmology: Creating What's To Come

[4/10] OptiMedica's Laser Cataract Surgery System To Be Featured In Three Clinical Presentations At ESCRS 2010

[5/10] Dr. Tom Tooma Purchases Interest In All 12 Southern California TLC Laser Eye Centers, Changing Name To NVISION Laser Eye Centers

[6/10] Bausch + Lomb Releases Single-Use Vitreoretinal Asymmetric Peeling Forceps

[7/10] New Data Will Help Predict Vision Loss In Glaucoma

[8/10] Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results

[9/10] ReVision's Fenretinide (RT-101) Reduced Incidence Of Choroidal Neovascularization By More Than 50 Percent In Patients With Geographic Atrophy

[10/10] Microplasmin Meets Primary Endpoint In Second Phase III Trial In VMA, Confirms Positive Findings Of First Trial